Introduction
Lung cancer is the leading cause of cancer death in the United States among both men and women. The projected number of lung cancer deaths in 2001 in the United States is 157 400, accounting for nearly 30% of all cancer deaths (Greenlee et al., 2001) . In fact, more people die each year from lung cancer than from breast, colorectal, prostate, and ovarian malignancies combined. Therefore, new treatment strategies are needed for this disease.
A potential new anticancer drug is the recently discovered tumor necrosis factor-related apoptosisinducing ligand (Apo2L/TRAIL). Apo2L/TRAIL is a cytokine which is closely related to TNF-a and FasL, members of the tumor necrosis factor family (Wiley et al., 1995) . Apo2L/TRAIL induces apoptosis via interacting with the death receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5), leading to the formation of the death-inducing signaling complex (DISC) with binding of caspase-8 (FLICE) (Kischkel et al., 2000; Sprick et al., 2000) . Recruitment of caspase-8 to the DISC activates its proteolytic properties, which initiates a cascade of protease activation involving enzymes such as caspase-3, promoting subsequent cleavage of death substrates and finally resulting in apoptosis . Apo2L/TRAIL can also bind to three other receptors TRAIL-R3 (DcR1 or TRID), TRAIL-R4 (DcR2 or TRUNDD), and the osteoprotegerin receptor OPG. Since these receptors contain no functional cytoplasmic death domain, they are presumed to primarily operate as competitive decoys for Apo2L/ TRAIL (Griffith and Lynch, 1998) . Though ratios of death and decoy receptors may contribute, it is unclear what renders cells susceptible or resistant to Apo2L/ TRAIL-induced apoptosis. Whereas various studies have shown that Apo2L/TRAIL induces apoptosis only in tumor but not normal cells (Walczak et al., 1999; Evdokiou et al., 2002) , other reports demonstrated cytotoxic effects of Apo2L/TRAIL against certain types of normal cells (Jo et al., 2000; Nesterov et al., 2002) . Tumor cells that are resistant to Apo2L/TRAIL can be sensitized to apoptosis induced by this cytokine by chemotherapeutic drugs Frese et al., 2002) and other agents (Rohn et al., 2001; Nam et al., 2002) . Various mechanisms can underlie this phenomenon, suggesting that Apo2L/TRAIL resistance may vary among tumor cells Rohn et al., 2001) .
In the present study, we demonstrate that lung cancer cell lines and primary tumor tissue of lung cancer patients but not normal human brochial epithelial (NHBE) cells can be sensitized for Apo2L/TRAIL with PG490 (triptolide), an agent purified from the Chinese herb Tripterygium wilfordii. PG490 was shown previously to potentiate the apoptosis-inducing effects of TNF-a and chemotherapeutic drugs in tumor cells (Lee et al., 1999; . Our data further suggest that activation of ERK2, a member of the mitogenactivated protein kinase family, is required for PG490-mediated sensitization to Apo2L/TRAIL-induced apoptosis.
Material and methods

Reagents
Soluble, nontrimerized Apo2L/TRAIL was kindly provided by Genentech (South San Francisco, CA, USA). PG490, U0126, and SB203580 were obtained from Alexis (San Diego, CA, USA).
Cell culture
The human lung cancer cell lines A549, NCI-H358, Calu1, and SkLu1 (American Type Culture Collection), were cultured at 371C and 5% CO 2 in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and antibiotics. NHBE cells were obtained from Biowhittaker (Walkersville, MD, USA). The cells were maintained in media recommended by the supplier and used within two to four passages.
Apoptosis assays
Cells were seeded at 1 Â 10 5 /well in 24-well plates and allowed to attach overnight. After stimulation for the indicated times, cells were harvested and assessed for apoptosis. For propidium iodide (PI) uptake, cells were resuspended in PBS, PI (Sigma, St Louis, MO, USA) was added to a final concentration of 10 mg/ml, and probes were immediately analysed by FACScan (Becton Dickinson, San Jose, CA, USA). AnnexinV (Alexis, San Diego, CA, USA) staining was performed as described previously (Frese et al., 2002) , followed by analysis by flow cytometry (Becton Dickinson, San Jose, CA, USA). Apoptotic nuclear changes were detected by terminal deoxynucleotidyltransferase-mediated fluorescin-dUTP nick end-labeling (TUNEL kit from Roche Diagnostics, Mannheim, Germany) and analysing cells by FACScan. For all flow cytometry experiments, a minimum of 10 4 cells were analysed.
For fluorometric assessment of caspase-3 activity, cells were lysed with ultrasound in a buffer containing 20 mm PIPES, pH 7.2, 100 mm NaCl, 1 mm EDTA, 10 mm DTT, 0.1% CHAPS, and 10% sucrose. Protein (40 mg) from cell lysates in a total of 20 ml was combined with 32 ml caspase assay buffer (312.5 mm HEPES, pH 7.5, 0.3% CHAPS, 3.1% sucrose), 2 ml of DMSO, 1 ml of 1 m DTT, 60 ml H 2 O, and 1 ml of synthetic DEVD-amc caspase-3 substrate (100 mm stock solution of DEVDamc in DMSO, Calbiochem, La Jolla, CA, USA). The emitted fluorescence at 301C was kinetically measured over a 50-min period using a Spectramax Gemini Fluorometer (Molecular Devices, Sunnyvale, CA, USA).
Determination of Apo2L/TRAIL receptor expression
Cells were harvested by short trypsinization, washed once with ice-cold PBS containing 1% BSA, and resuspended in 100 ml PBS with 1% BSA. Then, 5 mg of primary anti-Apo2L/TRAIL receptor antibody (R1-M271, R2-M413, R3-M430 and R4-M444, a gift from Immunex Corp., Seattle, WA, USA) was added. Control IgG isotypes (Immunotech, Marseille, France) were applied to assess nonspecific staining. After 30 min incubation on ice, cells were washed twice and incubated with FITC-labeled secondary antibody (Immunotech, Marseille, France). At least 10 4 cells were analysed by FACScan.
Immunoblot analysis
Equal amounts of protein were separated by denaturating gel electrophoresis and transferred to nylon membrane as described previously (Frese et al., 2002) . Protein detection was performed using the Immunoblot Chemiluminescence Reagent Plus (New England Nuclear, Life Science Products, Boston, MA, USA). The following antibodies were used: PARP (clone C-2-10, Biomol, Plymouth Meeting, PA, USA), caspase-3 (for reference Krajewska et al., 1997) , caspase-8 (clone C15, a gift from Professor P Krammer, DKFZ Heidelberg; for reference Scaffidi et al., 1999) , caspase-9 (clone 2-22, StressGen, Canada), phospho-ERK, and ERK (Cell Signaling Technology, Beverly, MA, USA). Secondary HRP-conjugated goat anti-rabbit (Biorad, Hercules, CA, USA) and goat anti-mouse (Sigma, St Louis, MO, USA) antibodies were used for detection. For stripping, membranes were incubated for 30 min at 501C in a buffer containing 62.5 mm Tris-HCl, pH 6.7, 2% sodium dodecyl sulfate, and 100 mm b-mercaptoethanol. Then the blots were washed and preblocked again.
ERK activity assay
For determination of ERK activity, samples of 250 mg of protein in a total volume of 500 ml of lysis buffer (20 mm HEPES, pH 7.6; 120 mm NaCl; 0.2 mm EDTA; 1% Triton X-100 and protease inhibitors) were incubated with 15 ml of immobilized anti-phospho (Thr202/ Tyr204) ERK monoclonal antibody with rotation for 7 h at 41C. Samples were washed twice with lysis buffer and once with ERK kinase buffer. Then, 50 ml of kinase buffer supplemented with 200 mm ATP and 2 mg GST-TRAIL and PG490 in lung cancer S Frese et al ELK-1 fusion protein was added. After an incubation of 30 min at 301C, 25 ml of 3 Â Laemmli buffer was added and samples were stored at À201C. Phosphorylation of GST-ELK-1 was analysed by Western blotting using 30 ml from each kinase reaction, and anti-phospho ELK-1 polyclonal antibody. The immobilized anti-phospho ERK antibody, GST-ELK-1, ATP, kinase buffer, and the anti-phospho ELK-1 antibody were obtained from Cell Signaling (Beverly, MA, USA).
Primary culture of lung cancer and normal lung tissue
All patients reported here gave their written consent to be included in this study. At the morning of resection, 1 Â 1 cm 2 pieces of gelfoam (Pharmacia and Upjohn, Kalamazoo, MI, USA) were placed in a 24-well plate. The gelfoam was allowed to soak with culture medium (DMEM with 10% FCS and antibiotics). Lung tumors and adjacent normal lung tissues of patients with nonsmall-cell lung cancer (NSCLC) were taken from the operating room immediately after resection. The specimens were dissected into 2-3 mm cubes. Per well, 50-55 mg of tissue was put on the gelfoam and plates were incubated at 371C with 5% CO 2 . The next day, stimulation was performed as indicated. At 48 h after stimulation, 200 ml per well alamar blue (Serotech, Raleigh, NC, USA) was added. After 72 h, medium was collected and the tissue was fixed in 5% formaldehyde. The viability of the tissue was measured via the metabolism of alamar blue using a Spectramax Gemini Fluorometer (Molecular Devices, Sunnyvale, CA, USA) at 590 nm emission wavelength.
Immunohistochemistry
Paraffin sections (2 mm) were placed on SuperFrost Plus slides (Roth, Karlsruhe, Germany). Slides were dewaxed before antigen retrieval with 15% acetic acid for 8 min at room temperature. After blocking of endogenous peroxidases with 3% H 2 O 2 for 5 min, slides were incubated with anti-PCNA antibody (Dako, Glostrup, Denmark), diluted in 1 : 1 TBS/PBS containing 0.5% BSA, for 3 h. For detection of the immunosignal, the PicTure-Plus kit (mouse, Zymed, South San Francisco, CA, USA) was used. Sections were counterstained with hematoxylin.
Statistical analysis
To evaluate synergistic effects in cell lines, that is, the interaction of Apo2L/TRAIL and PG490 on cell death frequencies, a logistic regression model (quasi-likelihood model; for reference McCullagh and Nelder, 1989) was applied. The effect of Apo2L/TRAIL and PG490 on the emission at 590 nm was examined using an analysis of variance model with emission as dependent and Apo2L/ TRAIL and PG490 as independent variables. Calculations were performed using S-PLUS v6 (Insightful Corp., Seattle, WA, USA).
Results
PG490 sensitizes lung cancer but not normal human bronchial epithelial cells for Apo2L/TRAIL-induced apoptosis
It has been shown previously that PG490 can sensitize tumor cell lines of different origin for apoptosis induced by TNF-a (Lee et al., 1999) and chemotherapy . The concentrations of PG490 in these studies ranged from 5 to 20 ng/ml. Based on these results, we first investigated whether PG490 can sensitize lung cancer cells for Apo2L/TRAIL-induced apoptosis. Treatment of Calu1, a cell line which has been demonstrated to be almost resistant to Apo2L/TRAIL (Frese et al., 2002) , with 20 ng/ml PG490 alone or in combination with 100 ng/ml Apo2L/TRAIL for 48 h resulted in massive cell death after combined but not after single treatment (Figure 1a-d and 2 ). Similar effects were observed in A549, NCI-H358, and SkLu1 cells. Statistical analysis for the interaction of PG490 and Apo2L/TRAIL revealed synergism in inducing cell death in all the four cell lines when using cotreatment with 20 ng/ml PG490 and Apo2L/TRAIL (Figure 2) . Interestingly, although treated under the same conditions, no sensitization to Apo2L/TRAIL-induced apoptosis was observed in normal human bronchial epithelial cells (Figures 1e-h and 2 ). Combined treatment with PG490 and Apo2L/TRAIL induces PARP and DNA cleavage and activates caspase-3 and caspase-8
Next we determined the characteristics of cells undergoing apoptosis induced by combined treatment with PG490 and Apo2L/TRAIL. In Calu1 cells, cleavage of the caspase substrate PARP was seen only upon treatment with the combination of 20 ng/ml PG490 and 100 ng/ml Apo2L/TRAIL. Moreover, fragments of activated caspase-3 (p17 and p12) and caspase-8 (p18) were only detectable after combination but not after single agent treatment (lane 6, Figure 3a) . Interestingly, the caspase-3 antibody also showed a fragment slightly smaller than 12 kDa with highest intensity in cells treated with 20 ng/ml PG490 alone (lane 5, Figure 3a) , which was most likely not active caspase-3 as demonstrated by DEVD cleavage assay (Figure 3b ). Finally, combined treatment with 20 ng/ml PG490 and 100 ng/ml Apo2L/TRAIL increased DNA cleavage in Calu1 cells by 53.3714.1% compared to 21.373.2% for PG490 and 2.870.7% for Apo2L/TRAIL alone (Figure 3c ). Figure 4 , lower panel).
ERK2 activation is necessary for PG490-mediated sensitization to Apo2L/TRAIL As Apo2L/TRAIL receptor expression does not account for sensitization to Apo2L/TRAIL-induced apoptosis by PG490, we presumed intracellular factors to be responsible for the demonstrated effects. One such potential intracellular target is the extracellular-regulated protein kinase 1 and 2 (ERK1/2), members of the family of mitogen-activated protein kinases. Activation of ERKs has been previously shown to inhibit Apo2L/ TRAIL-induced apoptosis (Tran et al., 2001) . Under the described conditions of cotreatment with Apo2L/ TRAIL and PG490, which efficiently induced apoptosis, ERK2 but not ERK1 was activated, as shown with an monoclonal antibody recognizing ERK dually phosphorylated at Thr202 and Tyr204 (Figure 5a ). ERK Figure 4 Apo2L/TRAIL receptor surface expression on Calu1 cells. Cells were treated with 100 ng/ml Apo2L/TRAIL and 20 ng/ ml PG490 alone or in combination for 24 h. Subsequently, cells were stained with monoclonal antibodies raised against the extracellular domain of Apo2L/TRAIL receptors R1-R4. Data were analysed by flow cytometry Figure 5 ERK activity is required for apoptosis induced by PG490 and Apo2L/TRAIL. (a) Calu1 were stimulated as indicated and phosphorylation of ERK was determined by immunoblotting with a monoclonal antibody recognizing ERK1/2 dually phosphorylated at Thr202 and Tyr204. To show an equal amount of nonphosphporylated ERK, the same blot was stripped and reblotted with a polyclonal antibody against ERK. (b) After stimulating and harvesting Calu1, activated ERK was immunoprecipitated from 250 mg of protein. Kinase activity in the immunoprecipitates was then determined by phosphorylation of GST-Elk-1 fusion protein and visualized subsequently by immunoblotting with a polyclonal antibody recognizing phosphorylated GST-Elk-1. (c) U0126 but not SB203580 can inhibit apoptosis induced by the combination of PG490 and Apo2L/TRAIL. Calu1 were stimulated for 24 h. Apoptosis was measured by annexinV staining followed by flow cytometry. Data represent mean7s.d. of three independent experiments with duplicate samples TRAIL and PG490 in lung cancer S Frese et al kinase activity assay (which involved immunoprecipitation of ERK and in vitro phosphorylation of ELK-1, followed by immunodetection of phosphorylated ELK-1) confirmed the activation of ERK in apoptotic cells (Figure 5b ). To address the question whether the demonstrated activation of ERK is relevant for apoptosis induced by Apo2L/TRAIL and PG490, we used U0126, an inhibitor of ERK activation, and SB203580, an inhibitor of p38. While 10 mm U0126 decreased the percentage of annexinV-positive cells resulting from treatment with Apo2L/TRAIL and PG490 from 43.373.4 to 26.072.8%, no effect on apoptosis induced by Apo2L/TRAIL and PG490 was observed with 10 mM SB203580 (Figure 5c ). The data suggest that ERK but not p38 is required for apoptosis induced by combination treatment with Apo2L/TRAIL and PG490.
NHBEs express Apo2L/TRAIL receptors R1 and R2 and show activation of ERK after treatment with PG490 and Apo2L/TRAIL To address the question why NHBE cells are not sensitized by PG490 to Apo2L/TRAILinduced apoptosis (Figure 2 ), we determined Apo2L/ TRAIL receptors on the surface of these primary lung cells. Whereas both Apo2L/TRAIL receptors R1 and R2 are expressed on NHBE, almost no expression of R3 and R4 was observed (Figure 6a ). Since R1 and R2 are expressed on NHBE as well as on Calu1 (Figure 4) , we next analysed the activity of ERK after treatment with PG490 and Apo2L/TRAIL. Figure 6b demonstrates that ERK is also activated in NHBE treated with the combination of PG490 and Apo2L/TRAIL. This might suggest that activation of ERK alone is not sufficient to induce cell death by PG490 and Apo2L/TRAIL.
Cotreatment with Apo2L/TRAIL and PG490 impairs viability and inhibits the proliferation of primary cultured NSCLCs Results obtained using established cell lines are often difficult to transfer into clinical application. Therefore, we tested the effect of combined treatment with Apo2L/TRAIL (200 ng/ml) and PG490 (10 and 20 ng/ml) in primary cultures of lung cancer and normal lung tissue from patients who underwent surgery. A portion of the tissue used for primary culture experiments was assessed by a pathologist to confirm diagnosis. With one exception, all tissues were clearly identified as normal lung or lung cancer tissue. The normal lung tissue from one patient with bronchoalveolar carcinoma contained a few cancer islets due to the locally spreading nature of this cancer. Viability of the cultured tissue was determined by alamar blue 72 h after stimulation with Apo2L/TRAIL and PG490. As shown in Figure 7 , the combination of Apo2L/TRAIL and PG490 killed primary cultured lung cancer, while had little effect on normal lung tissue. Analysis of variance revealed a significant linear trend toward greater cell death when the dose of PG490 was raised (two-sided P ¼ 0.014). Also, separated trend tests for Apo2L/ TRAIL showed a stronger correlation with cytokine dose and tumor kill when PG490 was given with Apo2L/ TRAIL (P ¼ 0.034) than without Apo2L/TRAIL (P ¼ 0.189). Using the same tests, no correlation between cell death and dose of Apo2L/TRAIL or PG490 was observed for cultured normal lung tissue. In addition, immunohistochemistry for proliferation nuclear cellular antigen (PCNA), which has been demonstrated to be a marker for proliferation in lung cancer specimens (Ishiwata et al., 2000) , was performed. Slides from nontreated cancer tissue and from tissue treated with Apo2L/TRAIL showed strong nuclear staining for PCNA (Figure 8a and b) . Whereas the signal for PCNA was markedly diminished in the tissue treated with 20 ng/ml PG490 (Figure 8e ), PCNA staining was completely missing after combined treatment with 20 ng/ml PG490 and Apo2L/TRAIL (Figure 8f ). These data provide evidence that treatment with Apo2L/TRAIL and PG490 may also inhibit proliferation of cultured primary lung cancer.
Discussion
Studies of Apo2L/TRAIL have raised hopes of developing new anticancer treatment strategies using this cytokine. Apo2L/TRAIL has marked selectivity for cytotoxic effects against cancer but not normal cells (Ashkenazi et al., 1999; Walczak et al., 1999) . However, a number of cancer cells are resistant to Apo2L/TRAILinduced apoptosis (Griffith and Lynch, 1998) . In a previous study from our group, we found that four of six lung cancer cell lines were susceptible to Apo2L/ TRAIL, though with wide variation. We could also show that Apo2L/TRAIL-induced apoptosis is enhanced when lung cancer cells where treated in combination with chemotherapeutic drugs (Frese et al., 2002) . In the present study, we report that another agent, PG490, can sensitize lung cancer cells to Apo2L/ TRAIL. PG490 is purified from the Chinese herb Tripterygium wilfordii, which has been used for its immunosuppressive and anti-inflammatory activity in traditional Chinese medicine. Although from our knowledge it has been not used in the purified form in humans so far, the usage as a herb might suggest that systemic administration of PG490 is possible. This is supported by two in vivo studies in rats involving use of oral (100 mg/kg) and intraperitoneal (250 mg/kg) administration of PG490 without observing severe side effects (Faul et al., 2000; Huynh et al., 2000) . In vitro it was found that PG490 induces apoptotic cell death in T lymphocytes but not in thymocytes, using concentrations up to 100 ng/ml (Yang et al., 1998) . While it might be presumed from these data that systemic administration of PG490 is feasible, questions could be raised about the possible side effects when given together with Apo2L/TRAIL. Our experiments using NHBEs as well as exvivo cultured normal lung tissue treated with PG490 and Apo2L/TRAIL suggest that the combination of these reagents is not toxic to normal lung cells. However, far more work is required to assess the possibility of toxicity to other types of normal cells using animal models in the future. Why some cells are susceptible to Apo2L/TRAIL and others are resistant, is controversially discussed in the literature and it seems that there exist striking differences in cells of various origins. Whereas some studies demonstrated c-FLIP expression to be responsible for resistance to Apo2L/TRAIL (Leverkus et al., 2000; Kim et al., 2002) , others could not confirm this idea (Zhang et al., 1999) . Consistent with these reports, we demonstrated recently that in the same lung cancer cell lines used here, endogenous c-FLIP is not involved in mediating resistance to Apo2L/TRAIL-induced apoptosis (Frese et al., 2002) .
A popular hypothesis for explaining the sensitivity to Apo2L/TRAIL envisions cancer-specific differences to ratios of death and decoy receptors as an important event (Evdokiou et al., 2002) . Indeed, several studies have reported that an increased susceptibility to Apo2L/ TRAIL is accompanied with an elevated expression of Apo2L/TRAIL-R1 and -R2, the two Apo2L/TRAIL receptors with functioning cytoplasmic death domain (Evdokiou et al., 2002; Griffith et al., 2002; Xiang et al., 2002) . Our data from the present study suggest that the reason for sensitization to Apo2L/TRAIL-induced apoptosis by PG490 is localized within the cell, rather than on the cell surface. While addition of Apo2L/ TRAIL ligand led to downregulation of R1 and R2 membrane receptors, expression was not influenced by PG490. Interestingly, Apo2L/TRAIL-R3 and -R4, which contain no functional death domain, were upregulated on the cell surface by PG490. Thus, one might have expected PG490 to decrease rather than increase the sensitivity of tumor cells to Apo2L/TRAIL, if ratios of death and decoy receptors accounted for the observed actions of PG490 on Apo2L/TRAIL-mediated apoptosis. Taken together, we conclude that intracellular factors explain the effects of PG490. In addition to c-FLIP, other intracellular factors potentially related to apoptosis induction by Apo2L/ TRAIL, include the family of mitogen-activated protein kinases, such as ERK1/2, p38, and JNK/SAPK. Mitogen-activated protein kinases are stimulated by a wide range of extracellular signals, regulating cell proliferation, differentiation, and cell survival (English et al., 1999; Chang and Karin, 2001 ). However, the mechanism how mitogen-activated protein kinases contribute to cell survival and apoptosis is not clear yet. A proapoptotic function for JUN/SAPK and p38 has been suggested, while ERK appears to play largely an antiapoptotic role (Xia et al., 1995) . Accordingly, it has been reported that inhibition of p38 by SB203580 prevents Apo2L/TRAIL-induced apoptosis in HeLa cells (Lee et al., 2002b) . In contrast, an antiapoptotic function for ERK has been shown for Apo2L/TRAIL (Tran et al., 2001) , as well as apoptosis induced by the chemotherapeutic drugs vinblastine (Stadheim et al., 2001) and paclitaxel (MacKeigan et al., 2000) . Unexpectedly, we observed a correlation between PG490-mediated sensitization to Apo2L/TRAIL and ERK activation. In addition, enhanced cell death induced by combined treatment with Apo2L/TRAIL and PG490 was inhibited by U0126, an inhibitor of ERK activation. SB203580, which inhibits p38 activation, had no effect on enhanced apoptosis induced by Apo2L/TRAIL and PG490. Thus, our results suggest that ERK might act under certain circumstances in a proapoptotic fashion. Similar data have been reported for cisplatin-induced apoptosis . However, we also analysed NHBEs which express both the Apo2L/ TRAIL receptors R1 and R2. While these nontumorigenic primary lung cells are almost resistant to the combined treatment of PG490 and Apo2L/TRAIL, we observed activation of ERK as it was seen in Calu1. These data suggest that activation of ERK alone is not sufficient to induce cell death, implying the existence of other cofactors that efficiently protect NHBE cells from apoptosis induced by PG490 and Apo2L/TRAIL. One of such potential intracellular candidates might be NFkB. In a recently published study, Lee and colleagues proposed NF-kB inhibition as the mechanism for PG490-mediated sensitization to Apo2L/TRAIL-induced apoptosis (Lee et al., 2002a) . However, assuming an inhibition of NF-kB by PG490 in NHBE, it would also not explain the resistance of these cells to the combined treatment with PG490 and Apo2L/TRAIL.
At the moment, it is not clear how under the described conditions ERK activation occurs. Considering the demonstrated effect of ERK inhibition by U0126, it would be likely that MEK, a tyrosine/threonine kinase that phosphorylates and activates ERK, and further upstream Raf and Ras are involved. To confirm this, we determined the kinase activity of MEK, Raf, and Ras. Surprisingly, using the same conditions demonstrating ERK activation, no difference in kinase activity of MEK, Raf or Ras was detected (data not shown). This means that ERK activity is elevated after treatment with PG490 and Apo2L/TRAIL without increased activity of MEK, Raf, and Ras. However, using U0126 ERK activation was shown to be MEK dependent. Similar data demonstrating the activation of ERK without increased kinase activity of the MEK/Raf/Ras kinase cascade have been observed for signal transduction of the follicle-stimulating hormone. Despite a lack of increased MEK activity, activation of ERK was MEK-dependent, which is explained by the following mechanism. In nonstimulated cells, ERK is bound to an inhibitory protein, which is a protein-tyrosine phosphatase. Stimulation leads to dissociation of the phosphatase from ERK, and subsequently to ERK activation mediated by MEK itself possessing a basal kinase activity which can be blocked by U0126 (Cottom et al., 2003) . Whether the 100-kDa protein-tyrosine phosphatase also is involved in PG490-mediated sensitization to Apo2L/TRAIL-induced apoptosis needs to be assessed.
In conclusion, we have shown that lung cancer cell lines and primary tissue of lung cancer but not NHBEs can be sensitized by PG490 to apoptosis induction by Apo2L/TRAIL. Synergistic induction of apoptosis by Apo2L/TRAIL and PG490 involves cleavage of caspase-8 and -3 and requires activation of ERK. The combined use of Apo2L/TRAIL and PG490 therefore warrants further evaluation as a potential new treatment strategy for lung cancer.
